Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review5,7-Dichlorokynurenic acid is a potent antagonist at the glycine site of the NMDA receptor (Ki = 79 nM vs. [3H]-glycine).
Sodium Salt also available.
5,7-Dichlorokynurenic acid is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。
分子量 | 258.06 |
公式 | C10H5Cl2NO3 |
储存 | Store at RT |
纯度 | ≥98% (HPLC) |
CAS Number | 131123-76-7 |
PubChem ID | 1779 |
InChI Key | BGKFPRIGXAVYNX-UHFFFAOYSA-N |
Smiles | OC(=O)C1=NC2=CC(Cl)=CC(Cl)=C2C(O)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
1eq. NaOH | 100 | ||
DMSO | 100 |
以下数据基于产品分子量 258.06。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.88 mL | 19.38 mL | 38.75 mL |
5 mM | 0.78 mL | 3.88 mL | 7.75 mL |
10 mM | 0.39 mL | 1.94 mL | 3.88 mL |
50 mM | 0.08 mL | 0.39 mL | 0.78 mL |
参考文献是支持产品生物活性的出版物。
Baron et al (1990) Activity of 5,7-dichlorokynurenic acid. A potent antagonist at the NMDA receptor-associated glycine binding site. Mol.Pharmacol. 38 554 PMID: 2172769
Moore et al (1990) Substituted kynurenic acid derivatives. Potent and selective antagonists at the glycine site on the NMDA receptor. Eur.Fed.Med.Chem. (under auspices of IUPAC) XIth I 29
If you know of a relevant reference for 5,7-Dichlorokynurenic acid, please let us know.
关键词: 5,7-Dichlorokynurenic acid, 5,7-Dichlorokynurenic acid supplier, Potent, NMDA, antagonists, glycine, site, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, 0286, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 5,7-Dichlorokynurenic acid 的部分引用包括:
Kenny et al (2009) The integrity of the glycine co-agonist binding site of N-MthD.-aspartate receptors is a functional quality control checkpoint for cell surface delivery. J Biol Chem 284 324 PMID: 18990687
Stevens et al (2010) Light-evoked NMDA receptor-mediated currents are reduced by blocking D-serine synthesis in the salamander retina. Cell Commun Signal 21 239 PMID: 20101193
Adamsky et al (2018) Astrocytic Activation Generates De Novo Neuronal Potentiation and Memory Enhancement. Cell 174 59 PMID: 29804835
Astorga et al (2015) An excitatory GABA loop operating in vivo. Front Cell Neurosci 9 275 PMID: 26236197
您是否知道使用了 Tocris 5,7-Dichlorokynurenic acid 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review 5,7-Dichlorokynurenic acid and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.